Ebola & African TB - An Interview With
Dr. Lawrence Broxmeyer, MD

Jeff Rense
Dr. Lawrence Broxmeyer, MD
11-6-14 


RENSE: Thank you for coming here today. Recently CDC director Tom Frieden,
in a press conference and answering a WXIA-TV reporter, apparently lost
focus for a moment but quickly corrected himself when he said: “Right now,
there's only one patient who has ever been diagnosed with TB -- I'm sorry,
with Ebola in the U.S. and that individual tragically died today.” 

Your feelings?

BROXMEYER: Where he alive today, that might be a good one to ask Sigmund
Freud. Certainly the topic of TB and in particular West African TB was
noticeably avoided when the US Centers for Disease Control and Prevention
(CDC) recently said: "Diagnosing Ebola in a person who has been infected for
only a few days is difficult, because the early symptoms, such as fever, are
nonspecific to Ebola infection and are seen often in patients with more
commonly occurring diseases, such as malaria and typhoid fever."

RENSE: Your focus has been in bringing awareness to the existing tubercular
pathogens Mycobacterium tuberculosis and Mycobacterium Africanum currently
raging in West Africa [See: http://rense.com/general96/ebooraf.html] and
their similarities, especially with their pleomorphic L-forms or
cell-wall-deficient forms, both physically and sign-and- symptom-wise to the
Ebola virus. But How can this 'virus' be a RAGING WILDFIRE of contagion in
West Africa and yet it has essentially made it to nowhere else?  Not the UK,
not Europe, not S America, not the US.

BROXMEYER: Different strains offer different virulence for populations for
different immune systems. In the case of the West African Ebola zone, where
the outbreak originated, almost half of all TB cases are caused by
Mycobacterium africanum—an unusual tuberculosis, exclusive to West Africa.
This is africanum’s home, where it can build on its ability to infect humans
as well as native species such as chimpanzees and African green monkeys. In
1970-71 the CDC estimated that tubercular infection in individuals in
contact with these and other non-human primates was 60 to 100 times that of
the population at large (Richardson, 1987). Both African monkeys and great
apes are susceptible to the Mycobacterium Tuberculosis Complex. But they are
not alone. Members of this same complex have been also isolated from fruit
bats, which I am told is a delicacy in West Africa.

That tubercular M. africanum can and has already caused TB in the USA, at
least in California, is a matter of record. Also there is a body of evidence
that M. africanum is of lower virulence than M. tuberculosis, requiring more
sustained contact, even among household members—certainly mirrored in the
current outbreak. Meanwhile, health officials continue to insist that
"casual contact" cannot transmit Ebola—precisely the same claim that they've
long made for TB.

RENSE: If long-standing African strains of tuberculosis are involved, then
why have they become so virulent now?

BROXMEYER: Failure to read the stitches on the fast ball. Just over
81percent of the Ebola deaths recorded globally have originated from Liberia
and Sierra Leone. While Liberian health officials warned as early as 2009
that TB was skyrocketing out of control, a mixed scientific coalition from
Sierra Leone and Germany cautioned that Sierra Leone's own tuberculosis
level was not only the highest in West Africa but was filled with resistant
strains of TB and tuberculous Mycobacterium africanum which had "reached an
alarming level…”raising the question of possible consequences" for a future
new TB epidemic. This basically went unheeded as the infectious strains
simmered. 

RENSE: Yet everyone here recovers from what has been labeled Ebola. ZMAPP?

BROXMEYER: ZMapp is manufactured from the tobacco plant and under
development as a treatment for Ebola. It has not yet been tested in a
clinical trial. Nor is it known whether it is effective to treat the disease
— or whether it is safe. It is manufactured by Kentucky BioProcessing, a
subsidiary of Reynolds American. 

However the idea is not new. In West Africa, extracts of the tobacco plant
nicotiana tobaccum, used as medicinal plant extract, have long been known to
be effective and inhibitory in the treatment of tuberculosis. This was
written up by Adeleye, Conubogu and Ayolabi, in the African journal of
Biotichnology in 2008.

RENSE: Again, everyone here 'recovers'… Something else?

BROXMEYER: Unfortunately, I’m not privy to these Ebola victims’ patient
charts. There has been talk of using serum from convalescent patients, which
I believe is not enough. Also antibiotics are mentioned, and often used.
Antibiotics of course should not work for viral disease, but several of the
antibiotics in current and frequent use do have activity against tubercular
involvement —the fluoroquinolone antibiotics, azithromycin and the
aminoglycosides among them.

RENSE: There are those that feel that Ebola might be being misdiagnosed
under other diagnoses…like malaria. 

BROXMEYER: In the case of malaria, there are serological and thick and thin
smears that must be performed. Diagnostics for typhoid or for that matter
Yellow Fever are also quite adequate. But it is in the ability of tests for
the viral hemorrhagic fevers (VHFs) such as Ebola and Marburg — to rule out
or even consider a possible cross-reaction making tubercular cases Ebola
positive — that things become dicey. As an example — while an instruction
booklet issued by the US Food and Drug Administration showed impressive
results for detecting and thereby being positive for known "Ebola" samples,
it sadly failed in its inadequate selection of those pathogens that might be
cross-reacting and therefore making for false-positive Ebola tests. The
instruction booklet, Version 2.0, which accompanied the new Ebola assay,
mentions that no bacterial cross-reactivity was observed in the human DNA or
any of the bacteria tested in their Table 51 — the problem being that
neither Mycobacterium tuberculosis or its related Mycobacterium africanum
appear in that Table 51.

Such diversion is no trivial point. As time went by, it became obvious that
attempts were in the pipeline to link the pathogenesis of Ebola and AIDS.
Peter Piot, the discoverer of Ebola also worked tirelessly to establish that
still another virus was behind AIDS. To this effect, his work on the HTLV-1
virus, which did not cause AIDS, went nowhere. But problems with the
HIV/AIDS diagnostic probes would have to be avoided with Ebola — at all
costs. For example, in the past, as veterinarian Myron "Max" Essex—the first
scientist to propose human immunodeficiency virus (HIV) testing—knew,
tuberculosis and its allied mycobacteria gave a false positive for HIV in
his tests in almost 70 per cent of cases. Such cross-reactivity between HIV
and tuberculosis was so significant that it forced Essex and his protégé,
Congo physician Oscar Kashala, to warn that the HIV screening test, the
enzyme-linked immunosorbent assay (ELISA) and the western blot results
"should be interpreted with caution when screening individuals with M.
tuberculosis or other mycobacterial species." According to WHO, 1/3 of the
world harbors TB. So you get the point.

RENSE: If such African-strains of tuberculosis are actually involved, then
why are they not being quickly picked-up in the more advanced diagnostic
capacity of countries like our own?

BROXMEYER: First, you are assuming that TB is even being considered and
therefore looked for. In my experience, this has simply not been the case.
You have patients coming from West Africa and doctors have been told to
rule-out Ebola and perhaps malaria. 

Secondly, current technology for mycobacterial diagnostics is advanced, but
unhappily far from bullet-proof. Mattman found a sharp increase in positive
tests for TB when special stains and cultures were used to detect its
preferred cell-wall-deficient forms, but these are not being routinely used
in most American diagnostic centers. Even the vaunted PCR (The polymerase
chain reaction) — designed to amplify a single copy or a few copies of a
piece of DNA, generating thousands to millions of copies of a particular DNA
sequence. — falls far short for detecting tubercular disease. And old
standbys like the present 5TU [5 Tuberculin Units] tuberculin skin test and
chest x-ray often are negative even in the face of full-blown disease.

RENSE: The CDC seems in general to be quite virus oriented. Your views?

BROXMEYER: This is nothing new. There was much the same viral passion there
— at that time over "influenza" — when, in 1990, a new multidrug-resistant
(MDR) tuberculosis outbreak took place in a large Miami municipal hospital.
Soon thereafter, similar outbreaks in three New York City hospitals left
many sufferers dying within weeks. By 1992, drug-resistant tuberculosis had
spread to deadly mini-epidemics in 17 US states, and was reported not by the
American press, nor the CDC — but by the international media as out of
control. It seems that the first rule of public health officials is not to
create panic — something which the mere mention of tuberculosis seems to do.
So they shy away from its mere mention.

RENSE: It would seem to me that such conflicts of those who would attribute
viruses to illness as opposed to those who would attribute them to
ultra-microscopic bacteria or mycobacteria goes back considerably before
that.

BROXMEYER: Yes. You have that right. In the words of respected historian Ton
van Helvoort, going forward into the 1930s and 1940s, the concept of
Laidlaw, Smith and Andrewes’s "filterable influenza virus" was subjected to
such criticism that its very foundations were threatened. And those threats
came from many fronts, but none greater than from Dr. Arthur Kendall,
director of Medical Research at Northwestern. Kendall, using his own culture
medium and the ultra-powerful Rife microscope ­ saw bacteria and not viruses
in influenza. 

RENSE: Vitamin C is mentioned unofficially as an Ebola treatment. Your
thoughts?

BROXMEYER: Everything in moderation, including Vitamin C, which is vitally
important to our health and immune system. Actually Linus Pauling’s interest
in Vitamin C grew from the research of biochemist Irwin Stone. Stone, would
eventually publish The Healing Factor: "Vitamin C" Against Disease.
According to Stone: "The bacteria causing tuberculosis (Mycobacterium
tuberculosis) was particularly sensitive to the lethal action of ascorbic
acid" — Vitamin C. But just how well Vitamin C, at the proper concentration
killed even drug resistant TB had to wait until 2013. In an unexpected
discovery, researchers at Albert Einstein College of Medicine determined
that Vitamin C, all by itself, killed both TB and drug resistant TB on
culture plates. The finding suggested that Vitamin C, added to existing TB
drugs could enhance and possibly shorten TB therapy. The study was published
in the online journal Nature Communications.

RENSE: Interesting. Thanks for stopping by. Deeply appreciate it. 

Regarding Ebola, we don’t have the definitive answer, but we sure have a lot
of questions, such as how such a deadly disease can enter America and be
rendered suddenly curable and impotent. I don't have the answers but I have
a LOT of questions.

BROXMEYER: Likewise.

 

 

EM

On the 49th Parallel          

                 Thé Mulindwas Communication Group
"With Yoweri Museveni, Ssabassajja and Dr. Kiiza Besigye, Uganda is in
anarchy"
                    Kuungana Mulindwa Mawasiliano Kikundi
"Pamoja na Yoweri Museveni, Ssabassajja na Dk. Kiiza Besigye, Uganda ni
katika machafuko"

 

_______________________________________________
Ugandanet mailing list
[email protected]
http://kym.net/mailman/listinfo/ugandanet

UGANDANET is generously hosted by INFOCOM http://www.infocom.co.ug/

All Archives can be found at http://www.mail-archive.com/[email protected]/

The above comments and data are owned by whoever posted them (including 
attachments if any). The List's Host is not responsible for them in any way.
---------------------------------------

Reply via email to